New Mouth

newmouth.com

NewMouth is owned and funded by Dentistry Brands LLC, an informational marketing company that specializes in producing authoritative medical content based on dental literature, accredited scientific journals, and current dental research data.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

CORVAL™ LAUNCHES NEW BIOPHARMA COMMERCIALIZATION PLANNING PLATFORM

Corval | September 22, 2021

news image

Corval LLC announced the launch of its cloud-based commercialization planning platform designed for early- to mid-stage biopharma companies. Created by industry veterans with deep experience in biopharma commercialization, the platform provides a technology-based approach that expedites the commercialization planning process and helps teams align on strategic decisions, timing, and future resourcing needs. I have spent my entire career in this space and been exposed ...

Read More

PHARMACY MARKET

ANTARES PHARMA ANNOUNCES FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO®

Antares Pharma, Inc. | February 04, 2022

news image

Antares Pharma, Inc. a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted its New Drug Application resubmission for TLANDO®, an oral treatment for testosterone replacement therapy. The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of March 28, 2022, under the Prescription Drug User Fee Act. TLANDO® was granted tentative approval from the FDA as a twice-daily...

Read More

BUSINESS INSIGHTS

TRIMAS CLOSES ON ACQUISITION OF OMEGA

TriMas | December 21, 2021

news image

TriMasannounced that it has closed the acquisition of Omega Plastics (“Omega”), a manufacturer of custom components and tooling for medical, as well as industrial applications, adding to TriMas’ Packaging group. Omega leverages its core injection molding capabilities, ISO Class 8 clean room and advanced in-house tool making capabilities, to provide its customers a faster product development cycle, from prototype development, testing and validation, to short...

Read More

PHARMA TECH

BLUESTAR GENOMICS RECEIVES CAP ACCREDITATION FOR ITS CLINICAL LABORATORY

Bluestar Genomics | October 11, 2022

news image

Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy tests focused on non-invasive detection of high-mortality cancers in high-risk patient populations, today announced it received accreditation for its clinical laboratory from the College of American Pathologists (CAP). The certification enables the company to serve physicians and patients globally as it works towards broad commercialization of its first test f...

Read More
news image

BUSINESS INSIGHTS

CORVAL™ LAUNCHES NEW BIOPHARMA COMMERCIALIZATION PLANNING PLATFORM

Corval | September 22, 2021

Corval LLC announced the launch of its cloud-based commercialization planning platform designed for early- to mid-stage biopharma companies. Created by industry veterans with deep experience in biopharma commercialization, the platform provides a technology-based approach that expedites the commercialization planning process and helps teams align on strategic decisions, timing, and future resourcing needs. I have spent my entire career in this space and been exposed ...

Read More
news image

PHARMACY MARKET

ANTARES PHARMA ANNOUNCES FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO®

Antares Pharma, Inc. | February 04, 2022

Antares Pharma, Inc. a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted its New Drug Application resubmission for TLANDO®, an oral treatment for testosterone replacement therapy. The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of March 28, 2022, under the Prescription Drug User Fee Act. TLANDO® was granted tentative approval from the FDA as a twice-daily...

Read More
news image

BUSINESS INSIGHTS

TRIMAS CLOSES ON ACQUISITION OF OMEGA

TriMas | December 21, 2021

TriMasannounced that it has closed the acquisition of Omega Plastics (“Omega”), a manufacturer of custom components and tooling for medical, as well as industrial applications, adding to TriMas’ Packaging group. Omega leverages its core injection molding capabilities, ISO Class 8 clean room and advanced in-house tool making capabilities, to provide its customers a faster product development cycle, from prototype development, testing and validation, to short...

Read More
news image

PHARMA TECH

BLUESTAR GENOMICS RECEIVES CAP ACCREDITATION FOR ITS CLINICAL LABORATORY

Bluestar Genomics | October 11, 2022

Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy tests focused on non-invasive detection of high-mortality cancers in high-risk patient populations, today announced it received accreditation for its clinical laboratory from the College of American Pathologists (CAP). The certification enables the company to serve physicians and patients globally as it works towards broad commercialization of its first test f...

Read More